Proteomic Analysis of Single Mammalian Cells Enabled by Microfluidicnanodroplet Sample Preparation and Ultrasensitive Nanolc-MS Ying Zhu, Geremy Clair,William B
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Recent Advances in Droplet-Based Microfluidic Technologies
micromachines Review Recent Advances in Droplet-based Microfluidic Technologies for Biochemistry and Molecular Biology 1, 1, 2, Joel Sánchez Barea y , Juhwa Lee y and Dong-Ku Kang * 1 Department of Chemistry, Incheon National University, Incheon 22012, Korea; [email protected] (J.S.B.); [email protected] (J.L.) 2 Department of Chemistry, Research Institute of Basic Sciences, Incheon National University, Incheon 22012, Korea * Correspondence: [email protected]; Tel.: +82-32-835-8094 These authors contribute equally to this article. y Received: 2 May 2019; Accepted: 18 June 2019; Published: 20 June 2019 Abstract: Recently, droplet-based microfluidic systems have been widely used in various biochemical and molecular biological assays. Since this platform technique allows manipulation of large amounts of data and also provides absolute accuracy in comparison to conventional bioanalytical approaches, over the last decade a range of basic biochemical and molecular biological operations have been transferred to drop-based microfluidic formats. In this review, we introduce recent advances and examples of droplet-based microfluidic techniques that have been applied in biochemistry and molecular biology research including genomics, proteomics and cellomics. Their advantages and weaknesses in various applications are also comprehensively discussed here. The purpose of this review is to provide a new point of view and current status in droplet-based microfluidics to biochemists and molecular biologists. We hope that this review will accelerate communications between researchers who are working in droplet-based microfluidics, biochemistry and molecular biology. Keywords: droplet-based microfluidic; biochemistry; molecular biology; digital PCR; biochip; biosensor; digital quantification; microfluidic; single cell analysis 1. -
Technology Development for Single-Molecule Protein Sequencing
National Advisory Council for Human Genome Research May 18-19, 2020 Concept Clearance for RFA Technology Development for Single-Molecule Protein Sequencing Purpose: The purpose of this initiative is to accelerate innovation, development and early dissemination of single-molecule protein sequencing (SMPS) technologies. The ultimate goal is to achieve technological advances to the level where protein sequencing data can be generated at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical research in general. This would enable analyses, such as deeper understanding of molecular phenotypes, identification of low abundance and ‘missing’ proteins, and true single-cell proteomics. This concept represents an ambitious and high-risk technology development challenge, and if successful, would provide a focused opportunity to transform the use of proteomics, in much the same way as modern next- generation nucleic acid sequencing (NGS) transformed genomics due to its high-throughput, low cost, and generalizability. Background: Through the Human Genome Project, and other efforts, NHGRI transformed biology by making genomics mainstream, with genomics now being a fundamental part of many studies of the biology of disease. Proteomics has not had the same widespread adoption, partially because of a lack of proteomics technologies that approach the scale of NGS, including improvements to the sensitivity and dynamic range of protein detection. The human proteome is extremely complex. A typical human cell expresses >10,000 unique protein gene products; and can contain ~100 times as many modified proteins, or proteoforms, for each gene product. In addition, the dynamic range of the proteome approaches seven orders of magnitude (from one copy per cell to ten million copies per cell) in tissues and cell lines, and up to ten orders of magnitude in blood plasma. -
Interfacing to Biological Systems Using Microfluidics
University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 12-2018 Interfacing to Biological Systems Using Microfluidics Peter Golden Shankles University of Tennessee, [email protected] Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Recommended Citation Shankles, Peter Golden, "Interfacing to Biological Systems Using Microfluidics. " PhD diss., University of Tennessee, 2018. https://trace.tennessee.edu/utk_graddiss/5315 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Peter Golden Shankles entitled "Interfacing to Biological Systems Using Microfluidics." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in Energy Science and Engineering. Scott T. Retterer, Major Professor We have read this dissertation and recommend its acceptance: Steven M. Abel, Mitchel J. Doctycz, Jennifer L. Morrell-Falvey Accepted for the Council: Dixie L. Thompson Vice Provost and Dean of the Graduate School (Original signatures are on file with official studentecor r ds.) Interfacing to Biological Systems Using Microfluidics A Dissertation Presented for the Doctor of Philosophy Degree The University of Tennessee, Knoxville Peter Golden Shankles December 2018 Copyright © 2018 by Peter Golden Shankles All rights reserved. -
Computational Proteomics: High-Throughput Analysis for Systems Biology
Pacific Symposium on Biocomputing 12:403-408(2007) COMPUTATIONAL PROTEOMICS: HIGH-THROUGHPUT ANALYSIS FOR SYSTEMS BIOLOGY WILLIAM CANNON Computational Biology & Bioinformatics, Pacific Northwest National Laboratory Richland, WA 99352 USA BOBBIE-JO WEBB-ROBERTSON Computational Biology & Bioinformatics, Pacific Northwest National Laboratory Richland, WA 99352, USA High-throughput proteomics is a rapidly developing field that offers the global profiling of proteins from a biological system. These high-throughput technological advances are fueling a revolution in biology, enabling analyses at the scale of entire systems (e.g., whole cells, tumors, or environmental communities). However, simply identifying the proteins in a cell is insufficient for understanding the underlying complexity and operating mechanisms of the overall system. Systems level investigations generating large-scale global data are relying more and more on computational analyses, especially in the field of proteomics. 1. Introduction Proteomics is a rapidly advancing field offering a new perspective to biological systems. As proteins are the action molecules of life, discovering their function, expression levels and interactions are essential to understanding biology from a systems level. The experimental approaches to performing these tasks in a high- throughput (HTP) manner vary from evaluating small fragments of peptides using tandem mass spectrometry (MS/MS), to two-hybrid and affinity-based pull-down assays using intact proteins to identify interactions. No matter the approach, proteomics is revolutionizing the way we study biological systems, and will ultimately lead to advancements in identification and treatment of disease as well as provide a more fundamental understanding of biological systems. The challenges however are amazingly diverse, ranging from understanding statistical models of error in the experimental processes through categorization of tissue types. -
A Flexible Microfluidic System for Single-Cell Transcriptome Profiling
www.nature.com/scientificreports OPEN A fexible microfuidic system for single‑cell transcriptome profling elucidates phased transcriptional regulators of cell cycle Karen Davey1,7, Daniel Wong2,7, Filip Konopacki2, Eugene Kwa1, Tony Ly3, Heike Fiegler2 & Christopher R. Sibley 1,4,5,6* Single cell transcriptome profling has emerged as a breakthrough technology for the high‑resolution understanding of complex cellular systems. Here we report a fexible, cost‑efective and user‑ friendly droplet‑based microfuidics system, called the Nadia Instrument, that can allow 3′ mRNA capture of ~ 50,000 single cells or individual nuclei in a single run. The precise pressure‑based system demonstrates highly reproducible droplet size, low doublet rates and high mRNA capture efciencies that compare favorably in the feld. Moreover, when combined with the Nadia Innovate, the system can be transformed into an adaptable setup that enables use of diferent bufers and barcoded bead confgurations to facilitate diverse applications. Finally, by 3′ mRNA profling asynchronous human and mouse cells at diferent phases of the cell cycle, we demonstrate the system’s ability to readily distinguish distinct cell populations and infer underlying transcriptional regulatory networks. Notably this provided supportive evidence for multiple transcription factors that had little or no known link to the cell cycle (e.g. DRAP1, ZKSCAN1 and CEBPZ). In summary, the Nadia platform represents a promising and fexible technology for future transcriptomic studies, and other related applications, at cell resolution. Single cell transcriptome profling has recently emerged as a breakthrough technology for understanding how cellular heterogeneity contributes to complex biological systems. Indeed, cultured cells, microorganisms, biopsies, blood and other tissues can be rapidly profled for quantifcation of gene expression at cell resolution. -
Molecular Biologist's Guide to Proteomics
Molecular Biologist's Guide to Proteomics Paul R. Graves and Timothy A. J. Haystead Microbiol. Mol. Biol. Rev. 2002, 66(1):39. DOI: 10.1128/MMBR.66.1.39-63.2002. Downloaded from Updated information and services can be found at: http://mmbr.asm.org/content/66/1/39 These include: REFERENCES This article cites 172 articles, 34 of which can be accessed free http://mmbr.asm.org/ at: http://mmbr.asm.org/content/66/1/39#ref-list-1 CONTENT ALERTS Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more» on November 20, 2014 by UNIV OF KENTUCKY Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml To subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/ MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, Mar. 2002, p. 39–63 Vol. 66, No. 1 1092-2172/02/$04.00ϩ0 DOI: 10.1128/MMBR.66.1.39–63.2002 Copyright © 2002, American Society for Microbiology. All Rights Reserved. Molecular Biologist’s Guide to Proteomics Paul R. Graves1 and Timothy A. J. Haystead1,2* Department of Pharmacology and Cancer Biology, Duke University,1 and Serenex Inc.,2 Durham, North Carolina 27710 INTRODUCTION .........................................................................................................................................................40 Definitions..................................................................................................................................................................40 Downloaded from Proteomics Origins ...................................................................................................................................................40 -
Clinical Proteomics
Clinical Proteomics Michael A. Gillette Broad Institute of MIT and Harvard Massachusetts General Hospital “Clinical proteomics” encompasses a spectrum of activity from pre-clinical discovery to applied diagnostics • Proteomics applied to clinically relevant materials – “Quantitative and qualitative profiling of proteins and peptides that are present in clinical specimens like human tissues and body fluids” • Proteomics addressing a clinical question or need – Discovery, analytical and preclinical validation of novel diagnostic or therapy related markers • MS-based and/or proteomics-derived test in the clinical laboratory and informing clinical decision making – Clinical implementation of tests developed above – Emphasis on fluid proteomics – Includes the selection, validation and assessment of standard operating procedures (SOPs) in order that adequate and robust methods are integrated into the workflow of clinical laboratories – Dominated by the language of clinical chemists: Linearity, precision, bias, repeatability, reproducibility, stability, etc. Ref: Apweiler et al. Clin Chem Lab Med 2009 MS workflow allows precise relative quantification of global proteome and phosphoproteome across large numbers of samples Tissue, cell lines, biological fluids 11,000 – 12,000 distinct proteins/sample 25,000 - 30,000 phosphosites/sample Longitudinal QC analyses of PDX breast cancer sample demonstrate stability and reproducibility of complex analytic workflow Deep proteomic and phosphoproteomic annotation for 105 genomically characterized TCGA breast -
Proteomics & Bioinformatics Part II
Proteomics & Bioinformatics Part II David Wishart University of Alberta 3 Kinds of Proteomics • Structural Proteomics – High throughput X-ray Crystallography/Modelling – High throughput NMR Spectroscopy/Modelling • Expressional or Analytical Proteomics – Electrophoresis, Protein Chips, DNA Chips, 2D-HPLC – Mass Spectrometry, Microsequencing • Functional or Interaction Proteomics – HT Functional Assays, Ligand Chips – Yeast 2-hybrid, Deletion Analysis, Motif Analysis Historically... • Most of the past 100 years of biochemistry has focused on the analysis of small molecules (i.e. metabolism and metabolic pathways) • These studies have revealed much about the processes and pathways for about 400 metabolites which can be summarized with this... More Recently... • Molecular biologists and biochemists have focused on the analysis of larger molecules (proteins and genes) which are much more complex and much more numerous • These studies have primarily focused on identifying and cataloging these molecules (Human Genome Project) Nature’s Parts Warehouse Living cells The protein universe The Protein Parts List However... • This cataloging (which consumes most of bioinformatics) has been derogatively referred to as “stamp collecting” • Having a collection of parts and names doesn’t tell you how to put something together or how things connect -- this is biology Remember: Proteins Interact Proteins Assemble For the Past 10 Years... • Scientists have increasingly focused on “signal transduction” and transient protein interactions • New techniques have been developed which reveal which proteins and which parts of proteins are important for interaction • The hope is to get something like this.. Protein Interaction Tools and Techniques - Experimental Methods 3D Structure Determination • X-ray crystallography – grow crystal – collect diffract. data – calculate e- density – trace chain • NMR spectroscopy – label protein – collect NMR spectra – assign spectra & NOEs – calculate structure using distance geom. -
RNA-Seq and Microfluidic Digital PCR Identification of Transcriptionally Active Spirochetes in Termite Gut Microbial Communities
4-1 RNA-Seq and microfluidic digital PCR identification of transcriptionally active spirochetes in termite gut microbial communities Abstract CO2-reductive acetogenesis in termite hindguts is a bacterial process with significant impact on the nutrition of wood-feeding termites. Acetogenic spirochetes have been identified as key mediators of acetogenesis. Here, we use high-throughput, short transcript sequencing (RNA-Seq) and microfluidic, multiplex digital PCR to identify uncultured termite gut spirochetes transcribing genes for hydrogenase-linked formate dehydrogenase (FDHH) enzymes, which are required for acetogenic metabolism in the spirochete, Treponema primitia. To assess FDHH gene (fdhF) transcription within the gut community of a wood-feeding termite, we sequenced ca. 28,000,000 short transcript reads of gut microbial community RNA using Illumina Solexa technology. RNA-Seq results indicate that fdhF transcription in the gut is dominated by two fdhF genotypes: ZnD2sec and Zn2cys. This finding was independently corroborated with cDNA inventory and qRT-PCR transcription measurements. We, therefore, propose that RNA-Seq mapping of microbial community transcripts is specific and quantitative. Following transcriptional assessments, we performed microfluidic, multiplex digital PCR on single termite gut bacterial cells to discover the identity of uncultured bacteria encoding fdhF 4-2 genotypes ZnD2sec and Zn2cys. We identified the specific 16S rRNA gene ribotype of the bacterium encoding Zn2cys fdhF and report that the bacterium is a spirochete. Phylogenetic analysis reveals that this uncultured spirochete, like T. primitia, possesses genes for acetogenic metabolism – formyl-tetra-hydrofolate synthetase and both selenocysteine and cysteine variants of formate dehydrogenase. Microfluidic results also imply a spirochetal origin for ZnD2sec fdhF, but further gene pair associations are required for verification. -
S41598-018-25035-1.Pdf
www.nature.com/scientificreports OPEN An Innovative Approach for The Integration of Proteomics and Metabolomics Data In Severe Received: 23 October 2017 Accepted: 9 April 2018 Septic Shock Patients Stratifed for Published: xx xx xxxx Mortality Alice Cambiaghi1, Ramón Díaz2, Julia Bauzá Martinez2, Antonia Odena2, Laura Brunelli3, Pietro Caironi4,5, Serge Masson3, Giuseppe Baselli1, Giuseppe Ristagno 3, Luciano Gattinoni6, Eliandre de Oliveira2, Roberta Pastorelli3 & Manuela Ferrario 1 In this work, we examined plasma metabolome, proteome and clinical features in patients with severe septic shock enrolled in the multicenter ALBIOS study. The objective was to identify changes in the levels of metabolites involved in septic shock progression and to integrate this information with the variation occurring in proteins and clinical data. Mass spectrometry-based targeted metabolomics and untargeted proteomics allowed us to quantify absolute metabolites concentration and relative proteins abundance. We computed the ratio D7/D1 to take into account their variation from day 1 (D1) to day 7 (D7) after shock diagnosis. Patients were divided into two groups according to 28-day mortality. Three diferent elastic net logistic regression models were built: one on metabolites only, one on metabolites and proteins and one to integrate metabolomics and proteomics data with clinical parameters. Linear discriminant analysis and Partial least squares Discriminant Analysis were also implemented. All the obtained models correctly classifed the observations in the testing set. By looking at the variable importance (VIP) and the selected features, the integration of metabolomics with proteomics data showed the importance of circulating lipids and coagulation cascade in septic shock progression, thus capturing a further layer of biological information complementary to metabolomics information. -
Microbes and Metagenomics in Human Health an Overview of Recent Publications Featuring Illumina® Technology TABLE of CONTENTS
Microbes and Metagenomics in Human Health An overview of recent publications featuring Illumina® technology TABLE OF CONTENTS 4 Introduction 5 Human Microbiome Gut Microbiome Gut Microbiome and Disease Inflammatory Bowel Disease (IBD) Metabolic Diseases: Diabetes and Obesity Obesity Oral Microbiome Other Human Biomes 25 Viromes and Human Health Viral Populations Viral Zoonotic Reservoirs DNA Viruses RNA Viruses Human Viral Pathogens Phages Virus Vaccine Development 44 Microbial Pathogenesis Important Microorganisms in Human Health Antimicrobial Resistance Bacterial Vaccines 54 Microbial Populations Amplicon Sequencing 16S: Ribosomal RNA Metagenome Sequencing: Whole-Genome Shotgun Metagenomics Eukaryotes Single-Cell Sequencing (SCS) Plasmidome Transcriptome Sequencing 63 Glossary of Terms 64 Bibliography This document highlights recent publications that demonstrate the use of Illumina technologies in immunology research. To learn more about the platforms and assays cited, visit www.illumina.com. An overview of recent publications featuring Illumina technology 3 INTRODUCTION The study of microbes in human health traditionally focused on identifying and 1. Roca I., Akova M., Baquero F., Carlet J., treating pathogens in patients, usually with antibiotics. The rise of antibiotic Cavaleri M., et al. (2015) The global threat of resistance and an increasingly dense—and mobile—global population is forcing a antimicrobial resistance: science for interven- tion. New Microbes New Infect 6: 22-29 1, 2, 3 change in that paradigm. Improvements in high-throughput sequencing, also 2. Shallcross L. J., Howard S. J., Fowler T. and called next-generation sequencing (NGS), allow a holistic approach to managing Davies S. C. (2015) Tackling the threat of anti- microbial resistance: from policy to sustainable microbes in human health. -
PROTEOMICS the Human Proteome Takes the Spotlight
RESEARCH HIGHLIGHTS PROTEOMICS The human proteome takes the spotlight Two papers report mass spectrometry– big data. “We then thought, include some surpris- based draft maps of the human proteome ‘What is a potentially good ing findings. For example, and provide broadly accessible resources. illustration for the utility Kuster’s team found protein For years, members of the proteomics of such a database?’” says evidence for 430 long inter- community have been trying to garner sup- Kuster. “We very quickly genic noncoding RNAs, port for a large-scale project to exhaustively got to the idea, ‘Why don’t which have been thought map the normal human proteome, including we try to put together the not to be translated into pro- identifying all post-translational modifica- human proteome?’” tein. Pandey’s team refined tions and protein-protein interactions and The two groups took the annotations of 808 genes providing targeted mass spectrometry assays slightly different strategies and also found evidence and antibodies for all human proteins. But a towards this common goal. for the translation of many Nik Spencer/Nature Publishing Group Publishing Nik Spencer/Nature lack of consensus on how to exactly define Pandey’s lab examined 30 noncoding RNAs and pseu- Two groups provide mass the proteome, how to carry out such a mis- normal tissues, including spectrometry evidence for dogenes. sion and whether the technology is ready has adult and fetal tissues, as ~90% of the human proteome. Obtaining evidence for not so far convinced any funding agencies to well as primary hematopoi- the last roughly 10% of pro- fund on such an ambitious project.